Follow along with the video below to see how to install our site as a web app on your home screen.
Note: This feature may not be available in some browsers.
where are you seeing that the dose was 12mg daily? From what I see it says once weekly. And 2% weight loss difference between 9 and 12mg over 68 weeks shows how quickly the deminishing returns hit. IMO past 8mg of reta ur just wasting ur money. If u need more appetite suppresion you should look to add sema or cagri.
I feel like the "reta doesn't have strong appetite suppression" mantra is more placebo / word-of-mouth than anything else and has spread like fire on the internet but very clearly isn't evidenced based. 12mg of reta is some serious shit and the dropout rate doesn't surprise me at all. In fact it seems like a poorly designed study, because they already had data from Phase 2 showing high dropout rate and therefore no incremental weight loss in the 12mg group (since dropouts are included in the averages).Surprising results given how many use it because they don’t feel strong appetite suppression.
Those other trials all to find non obesity conditions that’ll qualify for insure coverage.
In other pharma news, Wegovy 7.2mg (yes. Sema up to 7.2mg) and Orforgliplon awarded National Priority Vouchers by the FDA to speed up approval of drugs important for national priorities to 2-3 months instead of years.
![]()
FDA Awards Second Batch of National Priority Vouchers
The U.S. Food and Drug Administration today announced six additional awardees under the Commissioner’s National Priority Voucher (CNPV) pilot program.www.fda.gov
Great newsSurprising results given how many use it because they don’t feel strong appetite suppression.
Those other trials all to find non obesity conditions that’ll qualify for insure coverage.
In other pharma news, Wegovy 7.2mg (yes. Sema up to 7.2mg) and Orforgliplon awarded National Priority Vouchers by the FDA to speed up approval of drugs important for national priorities to 2-3 months instead of years.
![]()
FDA Awards Second Batch of National Priority Vouchers
The U.S. Food and Drug Administration today announced six additional awardees under the Commissioner’s National Priority Voucher (CNPV) pilot program.www.fda.gov
Typo. 12 mg weekly. I don’t think EL really thinks there’s a linear dose response up to 12 mg. I think they are all in a pissing match to see how high they can push the dosages.where are you seeing that the dose was 12mg daily? From what I see it says once weekly. And 2% weight loss difference between 9 and 12mg over 68 weeks shows how quickly the deminishing returns hit. IMO past 8mg of reta ur just wasting ur money. If u need more appetite suppresion you should look to add sema or cagri.
Sema has much higher binding affinity for glp1, that translate to much more fullness, being full for longer, and so forth. It absolutely is the stronger appetite suppressant. Reta is still superior for fatloss due to the insulin sensitivity (from the GIP) and mild fat burning from the glucagon tho.I feel like the "reta doesn't have strong appetite suppression" mantra is more placebo / word-of-mouth than anything else and has spread like fire on the internet but very clearly isn't evidenced based. 12mg of reta is some serious shit and the dropout rate doesn't surprise me at all. In fact it seems like a poorly designed study, because they already had data from Phase 2 showing high dropout rate and therefore no incremental weight loss in the 12mg group (since dropouts are included in the averages).
Also not surprising - EL makes no mention of proportion of lean mass loss. If you calculate the incremental weight loss from reta versus tirz in the Phase 2 studies, it is entirely lean mass on the 8mg+ doses - meaning individuals could actually have lost MORE fat on tirz. (And yes, I understand protein, strength training, etc. I'm talking about the population these medications are actually intended for).
Yes I think high dose Reta is not a great option for the general population who isn’t eating enough protein and not strength training. At some point with reta it seems the more you eat (especially carbs) the more weight you lose. I think the glucagon agonism is likely to lead to more LBM loss in the general population.I feel like the "reta doesn't have strong appetite suppression" mantra is more placebo / word-of-mouth than anything else and has spread like fire on the internet but very clearly isn't evidenced based. 12mg of reta is some serious shit and the dropout rate doesn't surprise me at all. In fact it seems like a poorly designed study, because they already had data from Phase 2 showing high dropout rate and therefore no incremental weight loss in the 12mg group (since dropouts are included in the averages).
Also not surprising - EL makes no mention of proportion of lean mass loss. If you calculate the incremental weight loss from reta versus tirz in the Phase 2 studies, it is entirely lean mass on the 8mg+ doses - meaning individuals could actually have lost MORE fat on tirz. (And yes, I understand protein, strength training, etc. I'm talking about the population these medications are actually intended for).
Yes I think high dose Reta is not a great option for the general population who isn’t eating enough protein and not strength training. At some point with reta it seems the more you eat (especially carbs) the more weight you lose. I think the glucagon agonism is likely to lead to more LBM loss in the general population.
End of the day people should take what they tolerate and what is covered by their insurance. Personally, I prefer Reta but if Tirz was the only option that would be fine also.
This is interesting. I wonder if it's completely offset by our population's use of AAS and weightlifting and high protein or if tirzepatide is still the better choice for fat loss.Also, Glucagon is a catabolic hormone. This can be offset with sufficient protein intake, but muscle loss is already an issue for the general GLP using public, who aren’t getting sufficient protein, Reta could make that slightly worse.
so was discontinuation rate
Translation: many people dropped out due to losing too much weight.Lilly said Triumph-4 discontinuation rates were highly correlated with baseline body mass index (BMI). The rates included discontinuations for perceived excessive weight loss. Limiting the analysis to patients with a BMI of 35 or higher at baseline, thereby excluding people with overweight and class 1 obesity, cut the rates to 8.8% and 12.1% for the low and high doses, respectively, compared to 4.8% with placebo.
Yes I think high dose Reta is not a great option for the general population who isn’t eating enough protein and not strength training. At some point with reta it seems the more you eat (especially carbs) the more weight you lose. I think the glucagon agonism is likely to lead to more LBM loss in the general population.
End of the day people should take what they tolerate and what is covered by their insurance. Personally, I prefer Reta but if Tirz was the only option that would be fine also.
More fat loss while eating a lot more than I could on tirz. It’s more conducive to bodybuilding (for me). Tirz destroyed my appetite at 7.5 mg per week. Reta I can slowly work up or down and get all the metabolic benefits with less appetite suppression.why do you prefer reta?
I think they also mentioned the skin sensitivity as a limiting side effect.Translation: many people dropped out due to losing too much weight.
Surprising results given how many use it because they don’t feel strong appetite suppression.
Absolutely moronic and just clear junkie behaviour.12mg weekly as has been stated. Daily would probably be a bad thing. I am experimenting right now with a reta/tirz combo which when combining the two, would be the "max dose."
*8mg reta/5mg tirz" two separate injects at the same time once a week.
Well, dosing in reta is generally 2, 4, 6, 8, 10, 12 and tirz it is 2.5, 5, 7.5, 10, 12.5, and 15.Absolutely moronic and just clear junkie behaviour.
Pinning 2 competing compounds, ill never understand you gymbros.
However, 18.2% of patients dropped out of the retatrutide study due to gastrointestinal side effects. In comparison, 6.2% of patients given a 15-milligram dose of tirzepatide dropped out, Risinger said. The discontinuation rates correlated with a higher body mass index, or BMI, at the start of the test and included patients who dropped out after "perceived excessive weight loss."https://www.investors.com/news/technology/eli-lillys-experimental-obesity-drug-cut-weight-by-23-7/